Dipeptidyl-peptidase IV activity is correlated with colorectal cancer prognosis

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Larrinaga, Gorka ^a,d   Perez, Itxaro ^a,d   Sanz, Begoña ^a,d   Beitia, Maider ^a,d   Errarte, Peio ^a,d   Fernández, Ainhoa ^a,d   Blanco, Lorena ^a,d   Etxezarraga, María C ^b,d   Gil, Javier ^a,d   López, José I ^c,d  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

^d BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DIPEPTIDYL PEPTIDASE IV; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DPP4 GENE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; UPREGULATION; APOPTOSIS; BIOSYNTHESIS; BLOOD; COLORECTAL TUMOR; EARLY CANCER DIAGNOSIS; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DIPEPTIDYL PEPTIDASE 4; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER;

EID: 84925438757     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119436     Document Type: Article

References (38)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics. CA Cancer J Clin. 2014; 64:104-117. doi: 10.3322/caac.21220 PMID: 24639052
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403. doi: 10.1016/j.ejca.2012.12.027 PMID: 23485231
3. Vargas AJ, Thompson PA. Diet and nutrient factors in colorectal cancer risk. Nutr Clin Pract 2012; 27: 613-623. doi: 10.1177/0884533612454885 PMID: 22892274
4. Kim EC, Lance P. Colorectal polyps and their relationship to cancer. Gastroenterol Clin North Am. 1997; 26: 1-17. PMID: 9119435
5. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113-130. PMID: 17204026
6. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg. 2002; 89: 845-860. PMID: 12081733
7. De la Fuente IM. Metabolic dissipative structures. In: Systems Biology of Metabolic and Signaling Networks: Energy, Mass and Information Transfer. Aon MA, Saks V, Schlattner U, eds. Springer Series in Biophysics 16, Springer New York, 2014, pp 179-212.
8. Carl-McGrath S, Lendeckel U, Ebert M, Röcken C. Ectopeptidases in tumor biology: A review. Histol Histopathol 2006; 21: 1339-1353. PMID: 16977585
9. Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 2002; 122: 376-386. PMID: 11832452
10. Murakami H, Yokoyama A, Kondo K, Nakanishi S, Kohno N, Miyake M. Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 8674-8679. PMID: 16361553
11. Larrinaga G, Blanco L, Sanz B, Perez I, Gil J, Unda M, et al. The impact of peptidase activity in clear cell renal cell carcinoma survival. Am J Physiol Renal Physiol 2012; 303: F1584-1591. doi: 10.1152/ajprenal.00477.2012 PMID: 23019229
12. Larrinaga G, Perez I, Ariz U, Sanz B, Beitia M, Errarte P, et al. Clinical impact of aspartyl aminopeptidase expression and activity in colorectal cancer. Transl Res 2013; 162: 297-308. doi: 10.1016/j.trsl.2013.07.010 PMID: 23948443
13. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci 2008; 13: 1634-1645. PMID: 17981655
14. Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 2009; 58: 1723-1747. doi: 10.1007/s00262-009-0728-1 PMID: 19557413
15. Varona A, Blanco L, Perez I, Gil J, Irazusta J, López JI, et al. Expression and activity profiles of DPPIV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are-type dependent. BMC Cancer 2010; 10: 193. doi: 10.1186/1471-2407-10-193 PMID: 20459800
16. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007; 16: 1935-1953. PMID: 17932341
17. Cordero OJ, Ayude D, Nogueira M, Rodríguez-Berrocal FJ, Páez de la Cadena M. Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer 2000; 80: 1139-1146.
18. De Chiara L, Rodríguez-Piñeiro AM, Rodríguez-Berrocal FJ, Cordero OJ, Martínez-Ares D, Páez de la Cadena M. Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer 2010; 10: 333. doi: 10.1186/1471-2407-10-333 PMID: 20584285
19. Javidroozi M, Zucker S, Chen WT. Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer. Dis Markers 2012; 32: 309-320. doi: 10.3233/DMA-2011-0889 PMID: 22674411
20. Lam CS, Cheung AH, Wong SK, Wan TM, Ng L, Chow AK, et al. Prognostic significance of CD26 in patients with colorectal cancer. PLoS One 2014; 9: e98582. doi: 10.1371/journal.pone.0098582 PMID: 24870408
21. De Chiara L, Rodríguez-Piñeiro AM, Cordero OJ, Vázquez-Tuñas L, Ayude D, Rodríguez-Berrocal FJ et al. Postoperative serum levels of sCD26 for surveillance in colorectal cancer patients. PLoS One 2014; 9: e107470. doi: 10.1371/journal.pone.0107470 PMID: 25210927
22. Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007; 13: 1736-1741. PMID: 17363526
23. Wikberg ML, Edin S, Lundberg IV, Van Guelpen B, Dahlin AM, Rutegard J, et al. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumor Biol 2013; 34: 1013-1020. doi: 10.1007/s13277-012-0638-2 PMID: 23328994
24. Larrinaga G, Perez I, Blanco L, López JI, Andrés L, Etxezarraga C, et al. Increased prolyl endopeptidase activity in human neoplasia. Regul Pept. 2010; 163: 102-106. doi: 10.1016/j.regpep.2010.03.012 PMID: 20362629
25. Larrinaga G, Blanco L, Perez I, Sanz B, Errarte P, Beitia M, et al. Prolyl endopeptidase activity is correlated with colorectal cancer prognosis. Int J Med Sci 2014; 11: 199-208. doi: 10.7150/ijms.7178 PMID: 24465166
26. Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012; 11: 257-266. doi: 10.1158/1535-7163.MCT-11-0340 PMID: 22323494
27. th Edition, Springer, New York.
28. Washington MK, Berlin J, Branton P, Bugart LJ, Carter DK, Fitzgibbons PL, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med. 2010; 133: 1539-1551. doi: 10.1043/1543-2165-133.10.1539 PMID: 19792043
29. Alponti RF, Frezzatti R, Barone JM, Alegre Vde S, Silveira PF. Dipeptidyl peptidase IV in the hypothalamus and hippocampus of monosodium glutamate obese and food-deprived rats. Metabolism 2011; 60: 234-242. doi: 10.1016/j.metabol.2009.12.031 PMID: 20153005
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248-254. PMID: 942051
31. van Hensbergen Y, Broxterman HJ, Hanemaaijer R, Jorna AS, van Lent NA, Verheul HM, et al. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intraal fluid. Clin Cancer Res 2002; 8: 3747-3754. PMID: 12473585
32. Candenas L, Seda M, Noheda P, Buschmann H, Cintado CG, Martin JD, et al. Molecular diversity of voltage-gated sodium channel alpha and beta subunit mRNAs in human tissues. Eur J Pharmacol 2006; 541: 9-16. PMID: 16750188
33. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034. PMID: 12184808
34. Thirunavukarasu P, Sukumar S, Sathaiah M, Mahan M, Pragatheeshwar KD, Pingpank JF, et al. Cstage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst. 2011; 103: 689-697. doi: 10.1093/jnci/djr078 PMID: 21421861
35. Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst 2012; 104: 1320-1334. doi: 10.1093/jnci/djs336 PMID: 22911669
36. Wickström M, Larsson R, Nygren P, Gullbo J. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci. 2011; 102: 501-508. doi: 10.1111/j.1349-7006.2010.01826.x PMID: 21205077
37. Nazarian A, Lawlor K, Yi SS, Philip J, Ghosh M, Yaneva M, et al. Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer. Mol Cell Proteomics 2014; 13: 3082-3096. doi: 10.1074/mcp.M114.038836 PMID: 25056937
38. Cordero OJ, Imbernon M, Chiara LD, Martinez-Zorzano VS, Ayude D, De la Cadena MP, et al. Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol 2011; 2: 245-261. doi: 10.5306/wjco.v2.i6.245 PMID: 21773075